Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Wall Street has a weakness for complexity. Multi-factor models, quantitative screens, AI-driven portfolio optimisers, and macro overlays all promise an edge that simpler approaches cannot deliver. Against this backdrop, the Dogs of the Dow stands as a quiet rebuke. No algorithm required. No premium data subscription. No investment bank on speed dial. Just ten blue-chip stocks, selected once a year by a single criterion, held for twelve months, and then rebalanced. And in 2025, this allegedly outdated strategy delivered a total return of 18.91%, beating both the Dow Jones Industrial Average at 14.92% and the S&P 500 at 17.88%.
The contrarian investor’s job is to notice when the crowd’s pursuit of complexity creates an opportunity in simplicity. The Dogs of the Dow has been offering that opportunity, quietly and consistently, for over three decades.
The Origins of the Strategy
The Dogs of the Dow was popularised by Michael O’Higgins in his 1991 book “Beating the Dow,” which remains the canonical text for anyone who wants to understand the underlying logic. The concept had been circulating in analyst circles before that. According to Simply Safe Dividends, analyst John Slatter published an article in The Wall Street Journal in 1988 highlighting the approach’s historical success, which seeded the idea in retail investor consciousness before O’Higgins codified it.
The mechanics are deliberately spare. On the last trading day of the year, you identify the ten highest dividend-yielding stocks among the thirty components of the Dow Jones Industrial Average. You invest an equal dollar amount in each of those ten stocks. You hold them for the full calendar year. Then you repeat the process, selling any stocks that have dropped off the top ten yield list and replacing them with new additions. Rebalance to equal weights. Start again.
That is the entire strategy. Three steps. No discretion required.
Why a High Yield on a Blue-Chip Is a Contrarian Signal
The logic of the strategy rests on a simple observation about how dividend yields are calculated. A stock’s dividend yield is its annual dividend payment divided by its current share price. For the same dividend payment, a lower share price produces a higher yield. When a blue-chip Dow component has an unusually high dividend yield relative to its peers, it almost always means the share price has been beaten down, not that the company has suddenly become more generous with its dividend.
As Dividend Power explains, a high yield in this context is a symptom of a stock that is out of favour. The market has sold it down for some reason, whether that is a difficult earnings period, sector headwinds, a CEO departure, or simply rotating capital chasing momentum elsewhere. The Dogs of the Dow strategy is built on the hypothesis that for the blue-chip companies in the Dow, temporary disfavour is usually exactly that, temporary.
The dividend acts as a floor. While the contrarian waits for sentiment to recover, the stock continues paying out cash. The yield on the beaten-down price is typically attractive, often more than double the broader index average. According to Benzinga’s analysis ahead of 2026, the average yield of the 2026 Dogs sits at 3.3%, compared to the Dow’s overall average yield of approximately 1.9% and the S&P 500’s average of roughly 1.3%. You are paid generously to wait.
Professor Jeremy Siegel of the Wharton School of Business has called this one of the most successful investing strategies of all time, a verdict that carries weight coming from one of the most rigorous academic voices in finance.
The 2025 Performance in Detail
The 2025 Dogs list was composed of: Verizon (VZ), Chevron (CVX), Amgen (AMGN), Cisco (CSCO), IBM, Johnson & Johnson (JNJ), Merck (MRK), Coca-Cola (KO), McDonald’s (MCD), and Procter & Gamble (PG). Five stocks rotated off the 2024 list (Intel, Walgreens, Dow Inc, 3M, and JPMorgan) and were replaced by the five names that had seen their yields climb into the top ten.
According to HORAN Wealth’s full-year analysis, nine of the ten Dogs generated positive returns in 2025. Only Procter & Gamble finished the year in the red, down 12.25%. The standout performers were IBM and Cisco, both of which generated returns in excess of 30%, well ahead of the S&P 500’s technology sector return of 24%. Johnson & Johnson and Amgen also delivered strong results in a year where the broader healthcare sector underperformed the index.
This is precisely how the strategy is supposed to work. IBM and Cisco entered the year as Dow Dogs because their prices had lagged, inflating their yields relative to peers. The market had written them off as legacy technology names losing ground to cloud-native competitors. Within twelve months, both had recovered as earnings beat expectations and investor sentiment shifted. The Dogs strategy captured that recovery without any active intervention on the investor’s part, simply because the rules required holding them for the full year.
The 2026 Dogs: What the List Says About Current Market Sentiment
Three stocks rotated off the 2025 list heading into 2026 as their prices recovered and their yields normalised. Cisco, IBM, and McDonald’s all graduated off the list, which in Dogs strategy terms is a success signal. They were replaced by Home Depot (HD), Nike (NKE), and UnitedHealth (UNH), three companies that the market has recently punished heavily enough to push their yields into the top ten.
As outlined by Dividend Power, the full 2026 Dogs list is: Verizon (VZ) at 6.8%, Chevron (CVX) at 4.5%, with Amgen, Johnson & Johnson, Merck, Coca-Cola, Procter & Gamble, Home Depot, Nike, and UnitedHealth completing the roster. The average yield across the group is 3.3% at the start of 2026.
Each of the three new additions has a specific story behind its demotion to Dog status, and each story is worth understanding because it illustrates both the opportunity and the risk embedded in the strategy.
UnitedHealth entered the list under deeply unusual circumstances. Its CEO Brian Thompson was killed in December 2024, and the company then dramatically cut its annual earnings forecast in April 2025, citing elevated medical costs in its Medicare Advantage plans. According to Contrarian Outlook’s analysis of the 2026 Dogs, the same pressures on profit margins from high medical utilisation are expected to persist in 2026. Former CEO Stephen Hemsley has returned to run the company, but recovery will require time.
Nike entered the list after a prolonged operational downturn. The company brought back veteran Elliott Hill as CEO in late 2024 to lead a turnaround strategy built on reconnecting with sport performance and rebuilding wholesale relationships. Current fiscal year estimates suggest earnings will barely cover the dividend before a projected rebound in fiscal 2027. Nike shares are yielding at levels rarely seen in the stock’s history, which is precisely the kind of signal the Dogs strategy is designed to identify.
Procter & Gamble, having been the lone negative performer among the 2025 Dogs, remains on the list for 2026. The consumer goods giant faces a growth deceleration as price hikes that sustained revenues through 2022 and 2023 can no longer be pushed further without volume losses.
One important structural observation for 2026: Dividend Power notes that 40% of the 2026 Dogs portfolio sits in the healthcare sector, while consumer defensive and consumer cyclical names account for another 20% each. This concentration is worth acknowledging, particularly given the policy uncertainty around healthcare margins and Medicare reimbursement rates. It is not a reason to abandon the strategy, but it is a reason to understand what you own and why.
Variations: The Small Dogs and the Dow 4
The core Dogs of the Dow strategy has spawned several well-known variations, each attempting to refine the signal and improve returns at the margin.
The Small Dogs of the Dow takes the ten Dogs and further filters them by share price, selecting only the five with the lowest absolute stock price among the group. The rationale is that lower-priced stocks within the already beaten-down group represent even more severe disfavour, and therefore offer larger mean-reversion potential. DogsoftheDow.com notes that over the current century, the Small Dogs have outperformed the Dogs of the Dow on a cumulative basis.
The Dow 4, sometimes called the Dow 5 with a modification, takes the five lowest-priced stocks from the Dogs list and removes the single highest-yielding stock if it is also the lowest-priced, on the theory that a stock occupying both positions simultaneously may be a structural laggard rather than a temporary one. Detailed analysis from Yahoo Finance on 2025 performance highlights Verizon as the classic example, the highest-yielding and lowest-priced Dog in both 2025 and 2026, returning only 1.9% in 2025 and described as dragging the portfolio’s performance. The Dow 4 filter explicitly avoids this situation.
The Honest Accounting: What the Strategy Does Not Do
The Dogs of the Dow deserves honest treatment, not cheerleading, and that means acknowledging its documented weaknesses.
First, the strategy does not outperform every year or even every decade. Simply Safe Dividends’ analysis shows the Dogs returned 11.6% annualised from 2012 to 2022, slightly trailing the Dow’s 12.2% and the S&P 500’s 12.5% over the same period. Since 2000, the average annual total return has been approximately 8.7%. These are respectable but not spectacular numbers over a benchmark period that happened to favour growth stocks heavily.
Second, the strategy’s universe is deliberately narrow. With only thirty stocks in the Dow, and only ten Dogs at any given time, concentration risk is real and visible. In 2026, a bad year for healthcare broadly, UnitedHealth, Johnson & Johnson, Amgen, and Merck could all move in the same direction and meaningfully drag the portfolio.
Third, the most important caveat of all: a high dividend yield on a Dow component is usually but not always a temporary mispricing. Occasionally, a company’s underlying business has deteriorated structurally, not cyclically. When that happens, the dividend gets cut, the yield disappears, and the value thesis collapses. The Dogs strategy provides no protection against the value trap. It is the investor’s responsibility to understand whether the disfavour is temporary or permanent.
The Contrarian Case for Staying Mechanical
None of these caveats are arguments against the Dogs of the Dow. They are arguments for approaching it with eyes open. The strongest case for the strategy is not that it produces the highest possible returns. It is that it enforces a discipline most investors consistently fail to maintain on their own.
It forces you to buy what is out of favour rather than what has already run. It forces you to hold for twelve months rather than reacting to every earnings release or macro headline. It taxes you efficiently by requiring only annual rebalancing, qualifying almost all gains for long-term capital treatment. And it anchors the portfolio in companies that have survived long enough to earn a place in the Dow Jones Industrial Average, a filter that already eliminates the vast majority of structural failures.
The 2025 result, 18.91% total return against the S&P 500’s 17.88%, is a reminder that the contrarian does not need a better model to beat the market. Sometimes all that is required is the discipline to buy what everyone else has decided to ignore, and the patience to wait.
